Table 1

Comparison of clinical characteristics of patients in each group

Characteristics

Group 1

PAH

Group 2

At risk

Group 3

ILD

Group 4

Controls

P value


Number (n)

15

30

19

30

N/A


Age at onset (years)

44.5 ± 12.9

51.5 ± 14.8

40.3 ± 15.6

40.6 ± 13.2

0.015a


Age at study (years)

63.3 ± 10.5

66.0 ± 11.8

51.1 ± 12.7

48.7 ± 10.1

< 0.0001b


Disease duration (years)

18.8 ± 13.5

14.5 ± 10.4

10.8 ± 7.9

7.8 ± 7.2

0.003c


Female, n (%)

12 (80)

25 (83)

14 (74)

30 (100)

0.04

Male, n (%)

3 (20)

5 (17)

5 (26)

0


Limited (n)

13

28

6

23

< 0.0001d

Diffuse (n)

2

2

13

7


ANA, n

14

27

17

30

0.43

Anti-Scl70, n

1

3

10

5

0.001e

Anti-cent, n

7

21

0

16

< 0.0001f


WHO FC

-I

0

5

0

25

N/A

-II

2

11

12

5

-III

11

14

6

0

-IV

2

0

1

0


Dis. Duration, disease duration; PAH, pulmonary arterial hypertension; WHO FC, World Health Organisation Functional Class; ANA, anti-nuclear antibody; anti-Scl70, anti- topoisomerase-1 antibody; anti-cent, anti-centromere antibody. aOlder age at SSc onset in at-risk group versus other groups. bOlder age at time of study in PAH group and at-risk groups versus others. cLonger disease duration at time of study in PAH group versus controls. dHigher proportion of patients with limited subtype in all groups except ILD. eHigher proportion of Scl-70-positive patients in ILD than other groups. fHigher proportion of centromere-positive patients in all groups compared with ILD.

Thakkar et al. Arthritis Research & Therapy 2012 14:R143   doi:10.1186/ar3876

Open Data